SCHEMBL22982541

SCHEMBL22982541

CNC(=O)C1(N(C)C(=O)OC(C)(C)C)CCCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22982543 0.77
SCHEMBL7019111 0.71 NPSR1 (0.37)
SCHEMBL16067775 0.71 NPSR1 (0.33)
SCHEMBL25178779 0.70 CTSD (0.31)
SCHEMBL15116608 0.70 CTSD (0.31)
SCHEMBL1770349 0.70 CTSD (0.31)
SCHEMBL22986154 0.70 GHSR (0.32)
SCHEMBL1770679 0.70
SCHEMBL28751471 0.70 NPSR1 (0.36)
SCHEMBL29112686 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002388-A1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) 2023-01-05 US disclosed
US-11420970-B1 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NOVARTIS AG (CH) 2022-08-23 US disclosed
EP-4013755-A1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS Novartis AG (CH) 2022-06-22 EP disclosed
WO-2021028854-A1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS NOVARTIS AG (CH) 2021-02-18 WO disclosed